Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02037256 · ClinicalTrials.gov registry record · NA
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
A NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT02037256 is a NA study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 23 participants.
The verdict
NCT02037256, a NA study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
Interventions
- PROCEDURE autologous hematopoietic stem cell transplantation
- BIOLOGICAL filgrastim
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-01-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02037256
The ClinicalTrials.gov registry entry for NCT02037256 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which autologous hematopoietic stem cell transplantation is the first listed.
NCT02037256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02037256 about?
NCT02037256 is a clinical study titled "Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma". This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
What is the current status of trial NCT02037256?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2011-07. Estimated completion is 2015-01-21.
What interventions are being tested in trial NCT02037256?
The interventions under investigation include: autologous hematopoietic stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), bortezomib (DRUG).
Who is sponsoring clinical trial NCT02037256?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.